UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 93

Sortiert nach

Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab

Journal of clinical oncology, 2005-02, Vol.23 (4), p.712-719

2005

Link zum Volltext

Verfügbarkeit prüfen

Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients

Journal of clinical oncology, 2003-03, Vol.21 (5), p.897-906

2003

Link zum Volltext

Verfügbarkeit prüfen

Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7985-7993

2005

Link zum Volltext

Verfügbarkeit prüfen

Ten-year follow-up of helium ion therapy for uveal melanoma

American journal of ophthalmology, 1998, Vol.125 (1), p.81-89

1998

Link zum Volltext

Verfügbarkeit prüfen

A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis

Journal of rheumatology, 2005-12, Vol.32 (12), p.2345

2005

Link zum Volltext

Verfügbarkeit prüfen

131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

The New England journal of medicine, 2005-02, Vol.352 (5), p.441-449

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract B77: Phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B77-B77

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

Blood, 2013-11, Vol.122 (21), p.1948-1948

2013

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Blood, 2013-11, Vol.122 (21), p.3920-3920

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6585-6585

2012

Link zum Volltext

Verfügbarkeit prüfen

Orbital metastases: diagnosis and course

British journal of ophthalmology, 1997-05, Vol.81 (5), p.386-390

1997

Link zum Volltext

Verfügbarkeit prüfen

Patient-specific whole-body dosimetry : Principles and a simplified method for clinical implementation

The Journal of nuclear medicine (1978), 1998-08, Vol.39 (8), p.S14-S20

1998

Link zum Volltext

Verfügbarkeit prüfen

Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy

Ophthalmology (Rochester, Minn.), 2002-10, Vol.109 (10), p.1850-1854

2002

Link zum Volltext

Verfügbarkeit prüfen

Abstract B185: Bench to bedside experience with TH-302: A tumor-selective hypoxia-activated prodrug as a promising treatment for prostate cancer

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.B185-B185

2009

Link zum Volltext

Verfügbarkeit prüfen

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors

Journal of clinical oncology, 1995-10, Vol.13 (10), p.2606-2612

1995

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma

American journal of clinical oncology, 2010-04, Vol.33 (2), p.111-116

2010

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

Cancer chemotherapy and pharmacology, 2008-05, Vol.61 (6), p.1019-1026

2008

Link zum Volltext

Verfügbarkeit prüfen

Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma : a prospective, randomized, dynamically balanced trial

Ophthalmology (Rochester, Minn.), 1993-10, Vol.100 (10), p.1547-1554

1993

Link zum Volltext

Verfügbarkeit prüfen

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy: Conjugate views compared with a hybrid method

Cancer, 2002-02, Vol.94 (4), p.1258-1263

2002

Link zum Volltext

Verfügbarkeit prüfen

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement

Leukemia & lymphoma, 2007, Vol.48 (2), p.342-348

2007

Link zum Volltext

Verfügbarkeit prüfen

sup 131^I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

The New England journal of medicine, 2005-02, Vol.352 (5), p.441

2005

Link zum Volltext

Verfügbarkeit prüfen

131 I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

The New England journal of medicine, 2005-02, Vol.352 (5), p.441-449

2005

Link zum Volltext

Verfügbarkeit prüfen

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin's Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy

Blood, 2004-11, Vol.104 (11), p.2631-2631

2004

Link zum Volltext

Verfügbarkeit prüfen

A Practical Methodology for Patient Release After Tositumomab and 131I-Tositumomab Therapy

The Journal of nuclear medicine (1978), 2002-03, Vol.43 (3), p.354-363

2002

Link zum Volltext

Verfügbarkeit prüfen

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine‐131 tositumomab therapy

Cancer, 2002-02, Vol.94 (S4), p.1258-1263

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 93

Suche als RSS-Feed

Aktive Filter

ThemaAged, 80 And Over

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(88)

Publikationsform

Artikel
(91)
Bücher
(1)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab

Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma Patients

Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab

Ten-year follow-up of helium ion therapy for uveal melanoma

A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis

131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

Abstract B77: Phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib

Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, and Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma

A Phase 1 Study Of TH-302, An Investigational Hypoxia-Targeted Drug, In Patients With Advanced Leukemias

Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias

Orbital metastases: diagnosis and course

Patient-specific whole-body dosimetry : Principles and a simplified method for clinical implementation

Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy

Abstract B185: Bench to bedside experience with TH-302: A tumor-selective hypoxia-activated prodrug as a promising treatment for prostate cancer

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors

A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma : a prospective, randomized, dynamically balanced trial

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy: Conjugate views compared with a hybrid method

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement

sup 131^I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

131 I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma

Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin's Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy

A Practical Methodology for Patient Release After Tositumomab and 131I-Tositumomab Therapy

Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine‐131 tositumomab therapy

Aktive Filter

Suchergebnisse filtern